Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the HCMV-TB Vaccine Candidate VIR-1778 in Adult Participants With Overall Good Health and Without HIV

NCT07818824 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT07818824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07818824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the HCMV-TB Vaccine Candidate VIR-1778 in Adult Participants With Overall Good Health and Without HIV
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 6, 2026
Completion date
June 30, 2028
Enrollment
116 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis